Trial Profile
Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada (Alemtuzumab)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Dec 2020
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 15 Dec 2020 Status changed from recruiting to discontinued as study funding was terminated.
- 27 Feb 2019 Status changed from not yet recruiting to recruiting.
- 09 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 31 Oct 2018.